Northwire Canada EditionMonday, July 13, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

NGEN · Price

Executive Summary

  • NervGen Pharma announced expanded data from its Phase 1b/2a CONNECT SCI Study showing durable, statistically significant functional improvements in chronic spinal‑cord‑injury (SCI) patients treated with NVG‑291 versus placebo.
  • Participants reported 2.6‑fold greater gains in overall hand function (GRASSP Total Score) and 3.7‑fold greater gains in quantitative prehension at Week 16, with benefits persisting up to 364 days post‑treatment.
  • The FDA confirmed multiple regulatory pathways for NVG‑291, underscoring a clear path toward accelerated approval of the first pharmacologic therapy for SCI.

Key Details

  • Study Design: 16‑week, double‑blind, placebo‑controlled trial; 20 participants (average 3.5 years post‑injury) received daily subcutaneous NVG‑291 or placebo for 12 weeks plus a 4‑week observation period.
  • Functional Outcomes – Week 16:
  • GRASSP Total Score: 2.6× greater mean improvement vs. placebo.
  • GRASSP Quantitative Prehension (hand function): 3.7× greater mean improvement vs. placebo.
  • Durability: Blinded exit interviews up to 364 days post‑Week 16 showed continued functional gains, increased independence, and reduced reliance on assistive devices.
  • Quality‑of‑Life Metrics:
  • Participant Global Impression of Change – 75% (6/8) NVG‑291 participants reported “much” or “very much” improvement vs. 33% (3/9) placebo.
  • Bladder control improvement: 67% (6/9) NVG‑291 vs. 22% (2/9) placebo.
  • Muscle spasticity reduction: 56% (5/9) NVG‑291 vs. 22% (2/9) placebo.
  • Neurophysiological Findings:
  • Startle MEPs showed a 142 % greater reduction in hyperactive reticulospinal signaling in the tibialis anterior (p=0.0062).
  • Hand (first dorsal interosseus) showed a 48 % greater reduction (p=0.0280).
  • Strong inverse correlation between reduced reticulospinal activity and increased corticospinal signaling in hands (R = ‑0.794, p = 0.006).
  • Regulatory Update: Completed FDA Type C meeting (Sept 2024); FDA indicated multiple pathways (including accelerated approval) are available for NVG‑291 given the unmet need. Anticipated End‑of‑Phase 2 meeting in early 2026.
  • Intellectual Property: Patent application filed to broaden IP protection around NVG‑291’s therapeutic mechanisms.
  • Additional Materials: Video documentation of 10‑meter walking assessments (baseline vs. post‑treatment) available at https://nervgen.com/presentations/.

Notable Quotes

“NVG‑291 continues to demonstrate the ability to restore clinically meaningful function and drive dramatic, real‑world improvements in daily independence and quality of life.” – Adam Rogers, MD, Interim CEO, NervGen Pharma

“The continued improvements… provide compelling evidence that recovery remains possible, even years after injury.” – Randall Kaye, MD, Chief Medical Advisor, NervGen Pharma

Read the original news release →

More from Nervgen Pharma Corp.